GLP-1 stands for glucagon-like peptide-1 — a hormone your gut releases after eating that signals fullness, slows digestion, and regulates blood sugar. GLP-1 receptor agonists are drugs that mimic and amplify this signal.
The two most commonly prescribed for weight loss are:
- Semaglutide (brand names: Wegovy for weight loss, Ozempic for type 2 diabetes) — weekly injection, ~15% average body weight reduction in clinical trials.
- Tirzepatide (brand names: Zepbound for weight loss, Mounjaro for diabetes) — weekly injection, activates both GLP-1 and GIP receptors, ~20–22% average body weight reduction in trials.
Why these numbers matter: Before GLP-1 medications, the best non-surgical intervention (intensive lifestyle modification) produced 5–10% weight loss on average. Tirzepatide's 20–22% approaches bariatric surgery outcomes — without the procedure.
GLP-1 medications work through several simultaneous mechanisms:
- Brain signaling: Bind to appetite receptors in the hypothalamus, reducing hunger signals and food cravings.
- Gastric emptying: Slow the rate at which food leaves your stomach, so you feel full longer after smaller meals.
- Insulin regulation: Stimulate insulin release in response to food (glucose-dependent), improving blood sugar stability.
- Dopamine modulation: Reduce the reward value of high-calorie foods — many patients report that food simply becomes less interesting.
Tirzepatide adds a second mechanism: it also activates GIP (glucose-dependent insulinotropic polypeptide) receptors, which appear to increase energy expenditure on top of reducing intake. This dual action is why tirzepatide produces stronger results.
The result is a significant sustained caloric deficit — not through willpower, but through biology.
| Semaglutide (Wegovy) | Tirzepatide (Zepbound) | |
|---|---|---|
| Mechanism | GLP-1 receptor agonist | GLP-1 + GIP dual agonist |
| Avg. weight loss | ~15% body weight | ~20–22% body weight |
| Dosing | Weekly injection, up to 2.4mg | Weekly injection, up to 15mg |
| Cardiovascular data | Proven CV risk reduction (SELECT trial) | CV data emerging (SURMOUNT-MMO) |
| FDA approval | Approved for chronic weight management | Approved for chronic weight management |
The right choice depends on your health history, prior medication experience, insurance coverage, and labs. Dr. Morris reviews all of this before recommending one over the other.
FDA guidelines specify two eligibility criteria for adult patients:
BMI ≥ 30
Any adult with a BMI of 30 or higher (obesity classification) typically qualifies for GLP-1 therapy.
BMI ≥ 27 + comorbidity
A BMI of 27–29.9 qualifies with at least one weight-related condition: type 2 diabetes, hypertension, high cholesterol, or sleep apnea.
Thyroid cancer history
GLP-1 therapy is contraindicated with personal or family history of medullary thyroid carcinoma or MEN2 syndrome.
Pancreatitis or pregnancy
History of pancreatitis or current/planned pregnancy are contraindications. Dr. Morris reviews each case individually.
These are guidelines, not guarantees. A full medical evaluation — including labs — is required. The intake questionnaire is the first step.
Clinical trial data (not marketing estimates):
- Semaglutide (STEP 1 trial): 14.9% average body weight reduction over 68 weeks in adults without diabetes. 1 in 3 patients lost more than 20%.
- Tirzepatide (SURMOUNT-1 trial): 20.9% average at the 15mg dose over 72 weeks. Nearly 1 in 2 patients achieved ≥20% body weight reduction.
For context: a 220-pound person losing 15% is ~33 lbs. Losing 20% is ~44 lbs. These are averages — some patients lose more, some less.
Most patients see measurable results within 4–8 weeks of reaching therapeutic doses. Full results develop over 9–18 months of treatment.
Important: Results are maintained with continued use. If medication is stopped without lifestyle changes in place, most patients regain weight within 12 months. This is why the functional medicine layer matters — it builds the habits and biology to sustain results.
Common (affecting 10–40% of patients):
- Nausea — most common, especially during dose escalation. Typically improves within 4–8 weeks.
- Constipation — manageable with hydration and fiber
- Diarrhea or loose stools — less common, usually transient
- Fatigue — often in early weeks as the body adjusts
- Mild injection-site reactions
Less common but monitor-worthy:
- Gallbladder disease — rapid weight loss can increase gallstone risk in any context
- Acute pancreatitis — rare; discontinue immediately and contact Dr. Morris if you develop severe abdominal pain
- Heart rate increase — slight resting heart rate elevation observed in some patients
Managing side effects: Most GI side effects are dose-dependent and can be minimized by eating smaller meals, avoiding high-fat foods, and maintaining a slow dose-escalation schedule. Dr. Morris adjusts dosing individually to reduce side effect burden.
The thyroid tumor risk noted in rodent studies has not been replicated in human data, but GLP-1 therapy is still contraindicated in patients with relevant personal or family history as a precaution.
Ready to find out if you qualify?
Complete the intake form — Dr. Morris's team reviews every submission and responds within 1–2 business days.
Dr. Morris's program is direct-pay — no insurance required, no surprise bills.
$299/mo
- Initial medical consultation
- Lab order & interpretation
- GLP-1 prescription management
- Monthly check-ins
$599/mo
- Everything in Essential
- Comprehensive metabolic panel
- Functional medicine coaching
- Sleep, stress & lifestyle protocol
- Bi-weekly provider access
Medication cost is separate: Semaglutide (Wegovy) and tirzepatide (Zepbound) are pharmacy medications billed independently. With commercial insurance coverage, many patients pay $25–$100/month. Without coverage, GoodRx and manufacturer savings programs can reduce out-of-pocket costs significantly.
See the full pricing breakdown on the GLP-1 program page.
It depends on your insurance plan and diagnosis:
- Most commercial insurance plans cover Ozempic/Mounjaro for type 2 diabetes but are inconsistent on coverage for obesity alone.
- Wegovy and Zepbound (the weight-loss branded versions) coverage varies widely — some plans cover with prior authorization, others exclude them entirely.
- Medicare expanded to cover anti-obesity medications for patients who also have cardiovascular disease in 2024.
- Medicaid coverage varies by state.
Dr. Morris's program fee ($299–$599/mo) is separate from pharmacy costs and is not insurance-billed. The program is structured for patients who want consistent access regardless of insurance approval — the cost is predictable from day one.
Most GLP-1 telehealth services follow a simple model: consultation, prescription, shipping. That's the full program.
Dr. Morris's program adds a functional medicine layer:
| Typical Telehealth | Dr. Morris | |
|---|---|---|
| Consultation | Basic intake | Full functional medicine evaluation |
| Lab work | Minimal or none | Comprehensive metabolic panel |
| Prescription | ✓ | ✓ |
| Root cause work | Not included | Sleep, stress, metabolic coaching |
| Long-term plan | Medication management | Protocol for sustaining results off-med |
GLP-1 medications are powerful tools, but the biology that drove the weight gain still needs to be addressed. Chronic stress, poor sleep, thyroid dysfunction, and insulin resistance all affect weight regulation. The functional medicine layer addresses those — and it's what determines whether you keep the weight off long-term.
Learn more on the GLP-1 program page or read about what functional medicine is.
Complete the intake questionnaire
Takes ~5 minutes. Covers your health history, current weight, goals, and GLP-1 interest. No commitment required.
Dr. Morris's team reviews your submission
Every intake is reviewed by a real person. You'll hear back within 1–2 business days to schedule your virtual consultation.
Virtual consultation via secure video
Dr. Morris reviews your health history, discusses your goals, answers questions, and orders any required lab work. No in-person visit required.
Labs + prescription initiated
Lab orders are placed after the consultation. Once results are reviewed, your GLP-1 prescription is initiated and sent to your pharmacy of choice.
Ongoing monitoring and coaching
Regular check-ins, dose adjustments, and functional medicine coaching throughout your program. You're not alone after the prescription.
Dr. Morris practices via telehealth and is available to patients nationwide. All consultations are conducted via secure video call — no in-person visit is required. You'll be asked to confirm your state of residence during the intake process so eligibility can be verified against applicable state telehealth regulations.
GLP-1 prescriptions require a medical evaluation regardless of provider. The $299/month Essential plan is the entry-level option — it includes the consultation, labs, and prescription management.
If you only want the prescription and prefer to manage everything else yourself, Dr. Morris's program may not be the right fit. There are GLP-1 prescription-only telehealth services if that's what you need. But if you want sustainable results — not just a prescription — the functional medicine layer is where that happens.